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Abstract
Trisomy 21 (T21) is associated in 40–45% of cases with heart defects, most commonly shunt lesions. These defects, if not repaired,
can lead to irreversible shunt-induced pulmonary hypertension (i.e. Eisenmenger syndrome [ES]). In ES patients, intracardiac repair
is no longer possible, but selective pulmonary vasodilators may increase exercise capacity and improve prognosis. This study aimed
to estimate the prevalence of cardiac defects and ES in adult T21 patients and to assess the impact of T21 on treatment modalities
and outcome in ES patients. A questionnaire was sent to 6906 Swiss physicians inviting them to indicate the number of adults with
T21 under their care (survey report). We also analyzed all adults with ES (with and without T21) included in the Swiss Adult
Congenital HEart disease Registry (SACHER) and studied the impact of T21 on the use of selective pulmonary vasodilators and
survival. In the survey, 348 physicians cared for 695 adult T21 patients. Overall, 24% of T21 survey patients were known to have a
cardiac defect, one in four with a defect had developed ES and 13% of those with ES were on specific pulmonary vasodilators. In
SACHER, ES was present in 2% of adults with congenital heart disease and selective pulmonary vasodilators were used in 68% of ES
patients with T21. In SACHER, survival during follow-up was worse with higher nt-proBNP levels (hazard ratio [HR]¼ 1.15 per
1000 units, 95% confidence interval [CI]¼ 1.02–1.29) and lower left ventricular ejection fraction (HR¼ 1.07 per percent decrease,
95% CI¼ 1.01–1.13). Age at inclusion and T21 did not affect survival. The prevalence of cardiac defects in adults with T21 in
Switzerland is half the prevalence in children. T21 is over-represented among adults with ES. Raised awareness of the therapeutic
options for T21 patients with ES is warranted.
Keywords
trisomy 21, adult congenital heart disease, pulmonary arterial hypertension, Eisenmenger syndrome, selective pulmonary
vasodilators, registry
Date received: 18 June 2018; accepted: 8 October 2018
Pulmonary Circulation 2018; 9(1) 1–8
DOI: 10.1177/2045894018811147
Trisomy 21 (T21) is the most common aneuploidy and
aﬀects one in 800–1000 live births.1,2 It is associated in
40–45% of cases with cardiovascular anomalies, most
commonly an atrioventricular septal defect (40–45%), or a
simple ventricular (30%) or atrial (15%) septal defect.3
Infant mortality in T21 has decreased substantially in the
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past 50 years, partially due to the increasing use of cardiac
surgery for repair of cardiovascular defects in early life.4 As
an example, mortality for infants with T21 in Sweden in the
ﬁrst year of life was 40% in 1970 and 4% in 2000.5 At the
same time, cardiac repair was oﬀered to 39% of aﬀected
children with defects in 1973–1977 and to 97% in the
years 1993–1997.6 In Switzerland, a similar evolution took
place: defect repair was the exception before the 1970s and
became clinical routine in the last two decades.
Some T21 children with cardiac defects and no repair in
early life survived to adult age and developed severe, irre-
versible shunt-induced pulmonary arterial hypertension
(PAH), i.e. Eisenmenger syndrome (ES).7 Intracardiac
repair for shunt defects is no longer possible at this stage;
therefore, families of adults with T21 and ES live with the
perception that ‘‘nothing else can be done.’’ However,
selective pulmonary vasodilators may increase exercise cap-
acity and improve prognosis in ES patients, including those
with T21.8,9
In 2013, the working group for adults and teenagers with
congenital heart disease of the Swiss Society of Cardiology
performed a nationwide survey among general practitioners
in Switzerland, inviting them to indicate the estimated
number of adults with T21 under their care, and the pro-
portion of such patients with known cardiac defects, with
ES, and on treatment with selective pulmonary vasodilators.
In a second step, we identiﬁed adults with ES included in the
Swiss Adult Congenital HEart disease Registry
(SACHER)10 followed at the University Hospitals Basel,
Bern, or Zurich, and investigated their treatment modalities
and outcome.
We hypothesized that treatment diﬀerences exist in ES
patients with respect to selective pulmonary vasodilators,
depending on whether they have T21 and whether they
receive specialized care.
Methods
Trisomy 21 survey. In spring 2013, a letter with four ques-
tions (Table 1) was sent to members of the ‘‘Schweizerische
Gesellschaft fu¨r Allgemeinmedizin (SGAM)’’ and of the
‘‘Schweizerische Gesellschaft fu¨r Innere Medizin (SGIM)’’.
The letter was in German, French, or Italian, depending on
the recipient’s address. The mailing was organized and
ﬁnanced by the pharmaceutical company Actelion Pharma
Schweiz (Baden, Switzerland). Physicians were asked to
send their responses by mail or fax to the Grown-Up
Congenital Heart (GUCH) disease unit of the Inselspital,
Bern. Due to the anonymous nature of the data, no ethical
approval was obtained for this questionnaire.
SACHER analysis. The SACHER is a nationwide regis-
try that was established in Switzerland in spring 2013 and
prospectively follows adults with congenital heart disease.10
Included are adults (aged >18 years) with structural con-
genital heart defects or Marfan syndrome. After informed
consent was obtained, anonymized clinical data were
entered in an online registry. The ethics review boards of
all participating hospitals approved the registry and subse-
quent analysis of data. The SACHER contained a total of
3476 patients on 1 September 2017. We analyzed in detail
data from 58 ES patients included at the GUCH units of the
University Hospitals Basel, Bern, or Zurich. These three
centers had included three of four SACHER patients
(2552 of 3476) at that time and all centers have specialized
programs for PAH on site. ES was deﬁned as PAH with a
non-restrictive intracardiac or extracardiac communication
and chronic cyanosis due to shunt reversal.11 The diagnosis
has been established and conﬁrmed in all cases by echocar-
diography. Cardiac catherization was not mandatory.
Patients’ histories were assessed for the following param-
eters: baseline characteristics at the time of inclusion in the
SACHER, survival status at 1 September 2017, defect anat-
omy and concomitant medication with a special focus on
selective pulmonary vasodilators. Of note, no uniform cri-
teria when to start selective pulmonary vasodilators were
used in the participating centers. The decision was left to
the treating physician. Nevertheless, all patients in
New York Heart Association (NYHA) functional class
(FC) III were oﬀered speciﬁc drugs. Exercise capacity was
assessed using the 6-min walking distance (6MWD) and the
NYHA FC. Echo ﬁndings at the time of last follow-up were
studied for the presence of right or left ventricular dysfunc-
tion, pericardial eﬀusion, and the degree of tricuspid regurgi-
tation. Any history of suspected or conﬁrmed paradoxical
embolism, hemoptysis, and sustained arrhythmia before
or after inclusion in the SACHER was documented.
Bloodwork including red blood count, renal function, thyroid
function, and NT-proBNP at the time of inclusion was noted.
Continuous data are shown as mean with standard devi-
ation or as median with the interquartile range (IQR),
as appropriate. Comparison between baseline characteristics
in ES patients with and without T21 were performed using
Table 1. Trisomy 21 questionnaire.
Question 1 How many adult patients (aged> 18 years) with
trisomy 21 are under your care?
Question 2 How many of these patients are known to have a
congenital cardiac defect?
Question 3 How many of these patients have an Eisenmenger
syndrome? (Eisenmenger syndrome is defined as
irreversible pulmonary arterial hypertension due
to the cardiac defect, accompanied by shunt
reversal and chronic cyanosis.)
Question 4 How many of your patients with trisomy 21 and
Eisenmenger syndrome receive specific vasodila-
tor therapies? Specific pulmonary vasodilators are
drugs like bosentan (Tracleer) or ambrisentan
(Volibris), sildenafil (Viagra or Revatio) or
tadalafil (Adcirca), or prostacylins like iloprost
(Ventavis or Ilomedin) or treprostinil
(Remodulin).
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the unpaired Student’s t-test for normally distributed con-
tinuous variables or with the Mann–Whitney U test for non-
normally distributed data. Distribution of categorical data
between groups was compared using the chi-square test.
Survival analysis was performed for all-cause mortality.
We calculated survival curves using the Kaplan–Meier
method; survival diﬀerences in ES patients with and without
T21 after inclusion in SACHER were compared using the
log-rank test. In a Cox proportional hazards model, age at
inclusion in SACHER, T21, and univariate signiﬁcant pre-
dictors of survival were entered in a multivariate regression
model. In all analyses, the null hypothesis was rejected for P
values< 0.05. All calculations were performed using
STATA 12 statistical software.
Results
Trisomy 21 survey. A total of 6906 letters were sent out.
After three months, 1097 responses were received (16%
response rate). The response rate varied between 8%
(region Appenzell Innerrhoden) and 32% (region Glarus),
with no major diﬀerences between the diﬀerent language
regions and between urban or rural areas (Fig. 1). Of the
responding physicians, 751 (68%) had no adult T21 patient
under their care (Table 2). A total of 348 general practi-
tioners cared for 695 adult T21 patients (median of one
patient per physician; IQR¼ 1–2). Of these 695 patients,
165 (24%) were reported to have a cardiac defect. A total
of 38 (23%) T21 patients (out of the 165 with a presumed
cardiac defect) were diagnosed as ES and ﬁve of them (13%)
were on speciﬁc pulmonary vasodilator therapies: three
patients were on Bosentan; one patient was on Sildenaﬁl;
and one patient was on dual therapy with Bosentan and
Iloprost inhalation at the time of the last visit.
SACHER results. Of the 58 patients with ES from
SACHER, 25 (43%) had T21, 34 (59%) of them were
women, 31 (53%) were in NYHA FC II, and 26 (45%)
were in NYHA FC III or IV. For one patient with ES,
the NYHA FC at inclusion was not documented. This ES
cohort represented 2% of all adults with congenital
heart disease included in SACHER at these centers.
The prevalence of T21 in all SACHER patients from
Basel, Bern, and Zurich was 2% (50/2552), signiﬁcantly
Fig. 1. Average response rate (in percent) to the T21 survey for different regions within Switzerland. The response rate was comparable in the
Italian, French, and German speaking parts of the country.
Table 2. Number of adult T21 patients under care.
T21 patients
under care (n) Responders (n (%))
Total T21 patients
under care (n)
0 751 (68) 0
1–2 293 (27) 371
3–4 29 (3) 97
5–6 14 (1) 73
7–12 9 (1) 85
13–30 3 (<1) 69
1099 responders 695 patients
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lower than the T21 prevalence found in the SACHER
patients with ES (25/58, 43%; P< 0.001). The mean age of
ES patients at the time of last follow-up or death was
39.8 13.0 years (age range¼ 17–67 years) (Table 3).
The most common heart defect in SACHER ES patients
was a ventricular septal defect (21 patients, 36%); the
second most common heart defect was an atrioventricular
septal defect (19 patients, 33%) (Table 4). As expected, there
was a diﬀerence in heart defect anatomy between ES
patients with and without T21; ES patients with T21 were
more likely to have an atrioventricular septal defect than
non-trisomy patients (70% vs. 9%, P< 0.001).
A total of 45 SACHER ES patients (78%) were on select-
ive pulmonary vasodilators: 23 patients were on single ther-
apy; 18 on dual therapy; and four on triple therapy. The
most commonly used vasodilators were endothelin-receptor
antagonists (bosentan or macitentan, no patients were on
ambrisentan) in 44 patients, followed by phosphodiester-
ase-5 (PDE5) inhibitors (sildenaﬁl or tadalaﬁl) in 26
patients. A total of ﬁve patients were put on riociguat;
four of them were previously on sildenaﬁl or tadalaﬁl.
Prostacylins or their analoga were used in seven patients
(six were on inhalation iloprost, one was switched to selex-
ipag, and another patient was newly started on selexipag).
The mean age when patients were started on pulmonary
vasodilators was 33.8 13.0 years and the mean duration
of drug therapy was 81.8 51.0 months. In SACHER, the
presence of T21 had no eﬀect on the proportion of patients
on selective pulmonary vasodilators, nor on the age when
this therapy was started (Table 3). ES patients without T21
were, however, more often on combination therapy or on
one of the newly developed pulmonary vasodilators, i.e.
macitentan, riociguat, or selexipag. The proportion of T21
patients with ES treated with selective pulmonary
Table 3. Characteristics of T21 vs. non-T21 patients in SACHER.
T21 No T21 P value
n 25 33
Age at last visit (years) 33.6 7.5 44.5 13.5 0.011
Body mass index (kg/m2) 24.8 5.2 22.9 4.3 0.122
Selective pulmonary vasodilators (n (%)) 17 (68) 28 (85) 0.128
Combination therapy (n (%)) 5 (20) 17 (52) 0.014
Newly developed drugs* (n (%)) 6 (24) 18 (55) 0.019
Age at start of selective pulmonary vasodilators (years) 30.0 9.6 36.2 14.4 0.138
Duration of pulmonary vasodilator use (months) 58.5 38.6 96.7 53.3 0.017
Resting oxygen saturation (%) 82.7 6.7 86.3 7.0 0.064
6MWD (m) 298 77 420 125 0.001
Tricuspid annular motion (mm) 19.1 4.5 17.0 4.5 0.112
Right ventricular dysfunction (n (%)) 2 (8) 17/32 (53) >0.001
Pericardial effusion (n (%)) 11 (44) 4 (12) 0.006
LVEF (%) 62 8 54 11 0.005
Nt-proBNP (pg/mL) 457 (249–1380) 526 (275–1770) 0.847
Hemoglobin (g/L) 201 28 175 34 0.003
Hematocrit (%) 60 8 52 12 0.004
Thyroid dysfunction (n (%)) 16 (64) 7 (21) 0.001
Values are presented as mean SD or as median and interquartile range unless otherwise indicated.
*Newly developed drugs: Macitentan (Opsumit), Riociguat (Adempas), Selexipag (Uptravi).
LVEF, left ventricular ejection fraction.
Table 4. Anatomy of cardiac defects of Eisenmenger patients in
SACHER.
Anatomy n
Ventricular septal defect 20
Complete atrioventricular septal defect 15
Functionally univentricular heart with unprotected
pulmonary circulation
6
Atrial septal defect, secundum type 5
Patent ductus arteriosus 3
Atrial septal defect and ventricular septal defect 2
Aortopulmonary window 2
Residual defect after ventricular septal defect closure 1
Atrial septal defect, primum type 1
Double outlet right ventricle 1
Common arterial trunc 1
Transposition of the great arteries and ventricular
septal defect
1
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vasodilators was signiﬁcantly higher in SACHER compared
to the T21 population reported in the nationwide survey (17/
25 vs. 5/38, P¼ 0.011).
Eleven patients (19%) had a history of presumed or
documented paradoxical embolism and 13 (22%) had sus-
tained atrial arrhythmias. The CHA2DS2-VASc score did
not diﬀer between patients with and without T21 (mean-
¼ 1.8 0.8) but was signiﬁcantly higher in patients with a
history of presumed paradoxical embolism (2.7 0.6) com-
pared to patients without such an event (1.7 0.7;
P¼ 0.001). None of the 11 patients with an event had a
score< 2. A total of 20 ES patients (35%) had bleeding
complications, most of the time hemoptysis (14 patients)
or gastrointestinal bleeding (three patients). There was no
diﬀerence in bleeding events between patients with and with-
out T21. The HAS-Bled score was signiﬁcantly higher in
patients with a bleeding history (2.0 1.0 vs. 0.7 0.9;
P< 0.001). None of the 20 (35%) ES patients with a
HAS-Bled score 0 suﬀered bleeding complications.
Overall, disease-related morbidity consisting of arrhyth-
mias, paradoxical embolism, or bleeding was observed in 33
(57%) patients. In a logistic regression model, disease-
related morbidity was only related to age (per 10 years of
age: odds ratio [OR]¼ 2.2, 95% conﬁdence interval
[CI]¼ 1.2–4.1), but not to T21 nor defect complexity.
A total of 10 (18%) ES patients died at a mean age of
34.1 10.1 years during the follow-up period after inclusion
in SACHER. There was no diﬀerence with respect to
gender, defect anatomy, the proportion of patients treated
with selective pulmonary vasodilators, supplemental oxygen
therapy, 6MWD, resting oxygen saturation, hemoglobin or
hematocrit, thyroid dysfunction, paradoxical embolism,
bleeding history, or arrhythmias between survivors and
non-survivors. However, echocardiography showed more
often right ventricular dysfunction and lower left ventricular
ejection fraction (LVEF) in non-survivors compared to sur-
vivors, and also the NT-proBNP diﬀered signiﬁcantly
(Table 5). In a Cox regression analysis corrected for age,
with T21, nt-proBNP levels and LVEF as predictors of
death during follow-up, only higher nt-proBNP levels
(hazard ratio [HR]¼ 1.15 per 1000 units, 95% CI¼ 1.02–
1.29) and lower ejection fraction (HR¼ 1.07 per percent
decrease, 95% CI¼ 1.01–1.13) were independent predictors
of outcome. In a Kaplan–Meier survival analysis, there was
again no survival diﬀerence in ES patients with and without
T21 (Fig. 4, P¼ 0.553).
Discussion
The reported prevalence of cardiac defects in Swiss adult T21
patients in our survey is half of the documented prevalence in
contemporary children with T21.3 In addition, T21 patients
are over-represented in SACHER among patients with ES.
If T21 ES patients are followed in specialized clinics, they are
as likely as the non-trisomy patients to receive selective
pulmonary vasodilators and the survival rates are compar-
able between these two groups of ES patients. In the
SACHER ES cohort, survival during follow-up was mainly
dependent on cardiac function, i.e. the degree of neurohor-
monal activation and particularly of LVEF.
Based on these observations one may conclude that
30–40 years ago, as in other countries, children born in
Table 5. Clinical characteristics of ES survivors vs. non-survivors in SACHER.
ES survivor ES non-survivor P value
n 48 10
Age at inclusion (years) 37.2 13.2 32.9 9.7 0.333
Body mass index (kg/m2) 24.1 4.8 21.9 4.2 0.164
Trisomy 21 (n (%)) 23 (48) 2 (20) 0.166
Selective pulmonary vasodilators 37 (77) 8 (80) 0.604
Resting oxygen saturation (%) 85.4 6.4 82.1 7.2 0.184
6 minutes walking distance (m) 384 123 330 130 0.264
Tricuspid annular motion (mm) 18.5 4.6 15.9 4.1 0.113
Right ventricular dysfunction (n (%)) 13/47 (27) 6 (60) >0.049
Pericardial effusion (n (%)) 14 (29) 1 (10) 0.427
LVEF (%) 59 9 49 14 0.006
Nt-proBNP (pg/mL) 453 (249–2819) 2928 (478–4437) 0.043
Hemoglobin (g/L) 184 41 183 40 0.923
Thyroid dysfunction (n (%)) 19 (39) 4 (40) 0.938
Embolic event (n (%)) 9 (19) 2 (20) 0.927
History of arrhythmias (n (%)) 11 (23) 2 (20) 0.634
Bleeding history (n (%)) 17 (35) 3 (30) 0.743
Values are presented as mean SD or as median and interquartile range unless otherwise indicated.
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Switzerland with T21 and a cardiac defect were less likely to
undergo cardiac surgery than children without T21, and
therefore faced increased childhood mortality and morbid-
ity. Another reason for the low prevalence of reported con-
genital heart disease in contemporary adults with T21 is the
possibility of under-diagnosis of such defects. Currently,
children born with T21 undergo routine echocardiography
after birth, even in the absence of a heart murmur.14 Many
adult T21 patients may not have undergone an echocardi-
ography in their childhood. Therefore, cardiac defects with
minor clinical ﬁndings and a paucity of symptoms in the ﬁrst
decades of life may yet not have been diagnosed. In a recent
Dutch study of 1158 adults with T21 living in residential
centers, the prevalence of cardiac defects documented in
the chart records was 16%, even lower than the reported
number of 23% in our survey.16 After performing an echo-
cardiography in 138 adults without any known defect, 24
new cardiac lesions were detected. The majority of cardiac
defects were valvular lesions, but EIGHT patients (7%) had
shunt lesions (secundum atrial or partial atrioventricular
septal defects, patent ductus arteriosus), requiring further
evaluation and treatment. Taking these undiagnosed defects
into account, the prevalence of cardiac defects in the Dutch
study of adults with T21 rose by 40%. No such study has yet
been performed in Switzerland, but it is also likely that Swiss
adults with Down’s syndrome have unrecognized congenital
heart defects. One might consider a routine echocardiog-
raphy in adult T21 patients with no previous cardiac evalu-
ation, as oﬀered to newborn children with Down’s
syndrome.
In patients with advanced pulmonary vasculopathy,
selective pulmonary vasodilator therapies are recommended
in pediatric and adult PAH guidelines,19,20 including com-
bination therapies. None of the guidelines deny such treat-
ment to T21 patients. In a recent multicenter study
investigating the outcome of> 1000 ES patients from
Europe and North America, two-third of patients were on
selective pulmonary vasodilator therapies at the end of
follow-up.11 In this large survey, 30% of all ES patients
had T21. A similar prevalence of T21 among ES patients
was also observed in Germany (33%).21 In the German
National Register for congenital heart defects, 58% of
patients with ES were treated with selective pulmonary
vasodilators and their use was independently associated
with better survival (HR¼ 0.44, 95% CI¼ 0.19–0.96).
Treatment-naı¨ve ES patients faced a 60–70% mortality at
10 years of follow-up. Similar to our study, there was
no diﬀerence in survival observed between ES with and
without T21.
Our study highlights the morbidity encountered in ES
patients: paradoxical embolism; arrhythmias; or bleeding
complications due to hemoptysis occurred in more than
half of all ES patients. As in other GUCH patients, also
in the SACHER ES patients with arrhythmias, the
CHA2DS2-VASc score was not predictive of stroke
events.22,23 However, the HAS-Bled score allowed to
deﬁne a subgroup of patients with low bleeding risks, i.e.
the ones with a score of 0. These ﬁndings need to be con-
ﬁrmed in a larger study cohort before they can be used to
guide our decision on anticoagulation strategies in ES
patients. In many ES patients, we face the dilemma of sig-
niﬁcant disease-related morbidity and mortality and missing
evidence-based treatment pathways. Management based on
expert opinions may be all we can oﬀer to improve outcome.
Therefore, referral of such complex patients to specialized
GUCH centers is recommended.
Our study has several limitations. In the nationwide
survey, the response rate was only 16%. We cannot
exclude an important bias; physicians without adult T21
patients under their care may have had less interest to
respond. In addition, some patients may have been
reported twice by diﬀerent practitioners. We could also
not verify if they diagnostic criteria for ES were correctly
applied in the survey patients. Assuming that the respond-
ing physicians are representative for the whole country,
4000–4500 adult T21 patients are expected to live in
Switzerland, yielding a prevalence of 5–5.5/10,000 inhabit-
ants. As comparison, a prevalence study in 2011 from
England and Wales estimated 26,600 adult T21 patients
among 56 million inhabitants, resulting in a prevalence of
4.8/10,000 inhabitants.24 Our extrapolated prevalence is
therefore comparable with other reports from Europe, sup-
porting the credibility of our ﬁndings. Another limitation
of this study is the small number of ES patients included in
SACHER. Analyzing multiple predictors of outcome was
only possible with statistical limitations. It is, however,
reassuring to see that most of our observations are in
line with reports from larger multicenter registries. It is
likely that some of the reported T21 patients with heart
defects in this survey were also included in SACHER. Due
to the anonymous nature of the survey, no cross-linking
was possible.
In conclusion, the prevalence of congenital heart disease
in adult patients with T21 living in Switzerland is half the
Fig. 2. Survival in Eisenmenger patients with and without T21 with
the corresponding CIs, after inclusion in SACHER. The timeline
denotes follow-up duration in months.
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expected prevalence. In the past, these patients were under-
treated or not timely diagnosed with congenital heart dis-
ease. As a consequence, adults with T21 and unrepaired
congenital heart disease patients face increased morbidity
and mortality. Raised awareness of potentially undiagnosed
congenital defects in such patients and of the therapeutic
options for T21 patients with ES is warranted.
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